Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FXI-siRNA
- Development stage
- Unknown
- Lead developer
- Carnegie Mellon University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
FXI-siRNA refers to small interfering RNA (siRNA) therapeutics designed to target and silence the expression of coagulation factor XI (FXI) mRNA, primarily in hepatocytes. By reducing circulating FXI protein levels, these agents inhibit the intrinsic pathway of the coagulation cascade, offering a potential anticoagulant and antithrombotic therapy with a reduced risk of bleeding compared to traditional anticoagulants. Several candidates are in development by various sponsors, including Vortosiran (RBD4059) by Suzhou Ribo Life Science, SRSD107 by Sirius Therapeutics, and CITY-FXI by City Therapeutics, alongside academic research evaluating its use in medical device anticoagulation.
- Other names
- anti-FXI siRNAcoagulation factor XI siRNAFactor XI siRNA
02
Targets
F9 (Coagulation Factor IX)F2 (Thrombin)F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on FXI-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FXI-siRNA.